NRG-HN008 / RHAN21009 / Cisplatin-Ineligible HNSCC / Michael Cummings
Basic Study Information
Purpose:Location: Highland Hospital
This phase I trial investigates the side effects and best dose of peposertib when
given together with radiation therapy in treating patients with head and neck cancer
that has spread to other places in the body (advanced) who cannot take cisplatin.
Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and
shrink tumors. This trial aims to see whether adding peposertib to radiation therapy
is safe and works well in treating patients with head and neck cancer.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search